Ariana P. Mullin, PhD

Ariana P. Mullin, PhD is the Executive Director of C-Path’s Huntington’s Disease Regulatory Science Consortium (HD-RSC). The HD-RSC is a collaboration formed by C-Path and the CHDI Foundation, Inc. (CHDI) with the aim of creating new tools and methods to advance efficient clinical development and address the regulatory needs for approval of HD therapeutics. A neuroscientist and electrophysiologist by training, Mullin received a B.S. in Neuroscience from Trinity College (Hartford, CT) and her PhD from Emory University (Atlanta, GA), where her work focused on the influence of genetic variations on synaptic vesicle trafficking dynamics. Dr. Mullin joined C-Path in 2017, prior to which she was with Acorda Therapeutics (Ardsley, NY) where she worked to develop and characterize in-house animal models of neurodegenerative diseases and evaluate potential beneficial effects of pipeline therapeutics, with a focus on multiple sclerosis and remyelination. Mullin is passionate about developing much-needed therapies across the neurodegenerative diseases, and is honored in her current role to lead and work with multidisciplinary teams comprised of academic subject matter experts, industry scientists, patients and patient advocates, and regulatory experts collectively working to accelerating therapeutic development for those affected by HD.